July 23rd 2024
AIC100 now has a regenerative medicine advanced therapy designation from the FDA for the treatment of recurrent anaplastic thyroid cancer.
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Brose and Laetsch Discuss Rare Actionable Targets in Patients With Thyroid Cancer
January 12th 2023During a Targeted Oncology case-based roundtable event, Marcia S. Brose, MD, PhD, and Theodore W. Laetsch, MD, discussed the data supporting the use of NTRK inhibitors in a patient with metastatic papillary thyroid cancer.
Read More
The Road to Overcoming Disparities in Thyroid Cancer Care
November 20th 2022In an interview with Targeted Oncology, Megan R. Haymart, MD, provided a recap of a symposium at the American Thyroid 2022 Annual Meeting and discussed disparities in thyroid cancer care, as well as potential solutions
Read More
NCCN Guideline Updates on Lenvatinib for the Treatment of Advanced RAI-R-DTC
November 16th 2022Dr Wirth reviews the updated NCCN guidelines that gave lenvatinib a category 1 recommendation for first-line treatment in advanced RAI-R-DTC and shares her experience of lenvatinib in clinical practice.
Watch
US Surgeons Embrace Radiofrequency Ablation for Thyroid Nodule Treatment
November 2nd 2022In an interview with Targeted Oncology, Jennifer Hong Kuo, MD, discussed the use of radiofrequency ablation to treat thyroid nodules and how research from Columbia University will guide further research around this topic
Read More
Psychiatric History May Prompt Patients’ Decisions for Faster Surgical Treatment in Thyroid Cancer
October 22nd 2022Psychiatric history may be an important factor for physicians to consider when counseling patients on their treatment options with thyroid cancer, according to a retrospective chart review.
Read More
Cancer Survivors May Be at Increased Risk for Secondary Primary Thyroid Cancer
October 21st 2022A study found that after their first primary malignancy diagnosis, cancer survivors are at a significantly increased risk for secondary primary thyroid cancer, with other half of cases occurring in the first 3 years.
Read More
Withholding RAI Therapy in Low-Risk Pediatric DTC Continues to Yield Comparable Remission Rates
October 20th 2022Following American Thyroid Association guidelines, a retrospective study confirmed that remission rates were comparable in pediatric patients with low-risk differentiated thyroid carcinoma who did and did not receive radioactive iodine therapy.
Read More
Addition of Atezolizumab to Vemurafenib/Cobimetinib May Improve Survival in BRAF V600E-Mutated ATC
October 20th 2022The combination use of a BRAF/MEK inhibitor plus checkpoint inhibitor immunotherapy did not meet median overall survival at 2 years, hinting at the combinations’ improved efficacy in patients with BRAF V600E-mutated anaplastic thyroid cancer.
Read More
Lenvatinib/Pembrolizumab Appears Safe in Metastasized Anaplastic Thyroid Carcinoma
September 13th 2022Data presented during the 2022 ESMO Congress showed lenvatinib plus pembrolizumab to elicit an objective response rate of 34.3% after 3 months in evaluable patients, meeting the primary end point of the phase 2 ATLEP trial.
Read More